7 analysts have expressed a variety of opinions on CME Gr CME over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 1 | 6 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 1 | 4 | 0 | 0 |
3M Ago | 0 | 0 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for CME Gr, presenting an average target of $254.14, a high estimate of $263.00, and a low estimate of $235.00. This upward trend is apparent, with the current average reflecting a 3.13% increase from the previous average price target of $246.43.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of CME Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Benjamin Budish | Barclays | Raises | Equal-Weight | $263.00 | $257.00 |
Kyle Voigt | Keefe, Bruyette & Woods | Lowers | Market Perform | $256.00 | $260.00 |
Patrick Moley | Piper Sandler | Raises | Overweight | $258.00 | $250.00 |
Ashish Sabadra | RBC Capital | Maintains | Sector Perform | $235.00 | $235.00 |
Christopher Allen | Citigroup | Lowers | Neutral | $250.00 | $255.00 |
Kyle Voigt | Keefe, Bruyette & Woods | Raises | Market Perform | $260.00 | $237.00 |
Benjamin Budish | Barclays | Raises | Equal-Weight | $257.00 | $231.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CME Gr. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CME Gr compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for CME Gr's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into CME Gr's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on CME Gr analyst ratings.
All You Need to Know About CME Gr
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
Key Indicators: CME Gr's Financial Health
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: CME Gr displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 18.43%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: CME Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 56.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CME Gr's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.23%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): CME Gr's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.69%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.12, CME Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.